Table 1.
Baseline characteristics according to the type of potassium binders.
| Variables | All patients | Propensity-matched patients | ||||
|---|---|---|---|---|---|---|
| ZSC group (n = 48) | CPS group (n = 84) | P value | ZSC group (n = 38) | CPS group (n = 38) | P value | |
| Age, years | 75 (69–84) | 79 (71–84) | 0.63 | 76 (70–84) | 80 (71–84) | 0.73 |
| Sex (female) | 9 (18.8) | 28 (33.3) | 0.11 | 8 (21.1) | 9 (23.7) | 1.00 |
| Disposition (Inpatient) | 9 (18.8) | 13 (15.5) | 0.64 | 8 (21.1) | 7 (18.4) | 1.00 |
| Follow-up period (week) | 6 (4–7) | 5 (4–7) | 0.52 | 6 (4–7) | 5 (4–7) | 0.62 |
| Dosage regimen | ||||||
| Dosage per day (g) | 5 (5) | 10 (5–15) | < 0.01 | 5 (5) | 10 (5–15) | < 0.01 |
| Number of doses per day | 1 (1) | 2 (1–3) | < 0.01 | 1 (1) | 2 (1–3) | < 0.01 |
| Cost per day (JPY) | 1,069 (1,069–1,069) | 132 (66–188) | < 0.01 | 1,069 (1,069–1,069) | 132 (66–195) | < 0.01 |
| Body weight (kg) | 60.4 (52.6–66.0) | 59.9 (48.7–68.3) | 0.98 | 58.1 (50.6–66.0) | 57.6 (47.9–66.3) | 0.60 |
| Mean BP (mmHg) | 92 (81–103) | 91 (81–101) | 0.51 | 91 (81–102) | 88 (82–101) | 0.37 |
| Comorbidities | ||||||
| Diabetes | 21 (43.8) | 32 (38.1) | 0.58 | 15 (39.5) | 13 (34.2) | 0.81 |
| Coronary artery disease | 14 (29.2) | 18 (21.4) | 0.40 | 10 (26.3) | 10 (26.3) | 1.00 |
| Congestive heart failure | 19 (39.6) | 39 (46.4) | 0.47 | 16 (42.1) | 22 (57.9) | 0.25 |
| Cerebrovascular disease | 7 (14.6) | 16 (19.0) | 0.64 | 5 (13.2) | 7 (18.4) | 0.75 |
| Malignancy | 18 (37.5) | 27 (32.1) | 0.57 | 16 (42.1) | 13 (34.2) | 0.64 |
| CCI | 4 (2–5) | 4 (3–5) | 0.93 | 4 (3–5) | 4 (2–5) | 0.80 |
| Underlying disease | ||||||
| Diabetic kidney disease | 14 (29.2) | 29 (34.5) | 0.87 | 9 (23.7) | 12 (31.6) | 0.40 |
| Nephrosclerosis | 15 (31.2) | 21 (25.0) | 14 (36.8) | 13 (34.2) | ||
| Glomerulonephritis | 4 (8.3) | 8 (9.5) | 2 (5.3) | 5 (13.2) | ||
| Others | 15 (31.2) | 26 (31.0) | 13 (34.2) | 8 (21.1) | ||
| Medications | ||||||
| RAS inhibitors | 29 (60.4) | 36 (42.9) | 0.07 | 20 (52.6) | 19 (50.0) | 1.00 |
| MR blockers | 7 (14.6) | 8 (9.5) | 0.40 | 4 (10.5) | 3 (7.9) | 1.00 |
| Loop diuretics | 7 (14.6) | 21 (25.0) | 0.19 | 6 (15.8) | 11 (28.9) | 0.27 |
| Thiazide | 3 (6.2) | 7 (8.3) | 0.75 | 3 (7.9) | 2 (5.3) | 1.00 |
| Beta blockers | 15 (31.2) | 24 (28.6) | 0.84 | 12 (31.6) | 14 (36.8) | 0.81 |
| Sodium bicarbonate | 7 (14.6) | 10 (11.9) | 0.79 | 6 (15.8) | 8 (21.1) | 0.77 |
ZSC, sodium zirconium cyclosilicate; CPS, calcium polystyrene sulfonate; BP, blood pressure; CCI, charlson comorbidity index; RAS, renin-angiotensin system; MR, mineralocorticoid receptor.